Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Italian Stock Exchange  >  DiaSorin SpA    DIA   IT0003492391

DIASORIN SPA (DIA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Italian Stock Exchange
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
75.35(c) 75.55(c) 77.6(c) 74.75(c) 74.6 Last
82 397 77 497 170 848 136 549 46 918 Volume
+2.52% +0.27% +2.71% -3.67% -0.20% Change
More quotes
Financials (EUR)
Sales 2018 700 M
EBIT 2018 213 M
Net income 2018 152 M
Finance 2018 190 M
Yield 2018 1,33%
Sales 2019 752 M
EBIT 2019 234 M
Net income 2019 169 M
Finance 2019 309 M
Yield 2019 1,45%
P/E ratio 2018 26,97
P/E ratio 2019 24,29
EV / Sales2018 5,69x
EV / Sales2019 5,14x
Capitalization 4 174 M
More Financials
Company
DiaSorin SpA engages in the development, production, and marketing of reagent kits for in vitro diagnostics.It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone... 
More about the company
Surperformance© ratings of DiaSorin SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on DIASORIN SPA
04/19DIASORIN : Conclusion treasury shares buy-back plan
PU
04/19DIASORIN : Weekly report treasury shares buy-back
PU
04/06DIASORIN : Weekly report treasury shares buy-back
PU
03/20DIASORIN : 65-- Cost Per Test Diasorin Reagents
AQ
03/02DIASORIN SPA : annual earnings release
01/30DIASORIN : Signs an agreement with the italian tax authority granting tax relief..
PU
2017DIASORIN : Federal Contracts Awarded by Federal Agencies in Texas (Dec. 22)
AQ
2017DIASORIN : MILITARY $92,935 Federal Contract Awarded to DiaSorin Molecular
AQ
2017DIASORIN : Launches a new simplexa bordetella direct molecular test
PU
2017DIASORIN : Resignation of a Strategic Executive of the Company
PU
More news
Sector news : Diagnostic & Testing Substances
04/19China May Request Minor Restrictions for Essilor Merger, Says Luxottica Chair..
DJ
04/19LUXOTTICA : chairman says China may seek 'minor restrictions' to clear Essilor d..
RE
04/04Smith & Nephew picks new CEO who sold his last company
RE
03/12Sensirion, Medartis to raise cash in Swiss IPO boom
RE
03/12STRAUMANN : Medartis to use IPO proceeds to expand amid rising implant demand
RE
More sector news : Diagnostic & Testing Substances
Latest Tweets
04/19DiaSorin : Weekly report treasury shares buy-back  
04/06DiaSorin : Weekly report treasury shares buy-back  
02/15Jefferies Group Sets Diasorin FY2017 Earnings Estimates at $3.53 EPS.  
01/08BRIEF-Qiagen, DiaSorin partner in automated tuberculosis detection  
01/08BRIEF-Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagn.. 
More tweets
Qtime:64
News from SeekingAlpha
03/08Diasorin SPA ADR 2017 Q4 - Results - Earnings Call Slides 
2017Diasorin SPA ADR 2017 Q3 - Results - Earnings Call Slides 
2017DiaSorin (DSRLF) Investor Presentation - Slideshow 
2016Winner And Losers Among Italian Companies 
2016Diasorin SPA ADR 2016 Q3 - Results - Earnings Call Slides 
Chart DIASORIN SPA
Duration : Period :
DiaSorin SpA Technical Analysis Chart | DIA | IT0003492391 | 4-Traders
Technical analysis trends DIASORIN SPA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 78,5 €
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
Carlo Rosa Chief Executive Officer, Executive Director & GM
Gustavo Denegri Chairman
Piergiorgio Pedron Chief Financial Officer & Senior Corporate VP
Chen Menachem Even Executive Director & SVP-Commercial Operations
Franco Moscetti Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DIASORIN SPA0.81%5 128
BIOMERIEUX-13.78%9 365
AUTOBIO DIAGNOSTICS CO LTD6.16%3 770
MACCURA BIOTECHNOLOGY CO LTD--.--%2 179
SIEGFRIED HOLDING AG5.56%1 476
GETEIN BIOTECH INC2.37%1 296